Slide TRIAL MIXED UNIT
(CIPF - FIHGUV)
Carlos Camps Herrerro





The Scientific Collaboration in the field of Biomedicine and Health Sciences between the Prince Felipe Research Center Foundation (FCIPF) and the  General University Hospital of Valencia Research Foundation (FIHGUV) within the framework of the Translational Research Unit in Tumor Oncology and Immunology (TRIAL Mixed Unit) has been in force since July 19, 2019. Currently, we are working on several research lines in our CIPF laboratory and facilities:

The search for new molecular biomarkers in cancer-focused on early diagnosis and the search for prognostic-predictive factors of treatment response through different omic approaches (genomics, transcriptomics, metabolomics).

Immuneregulation, cancer, and tumor microenvironment. Multidimensional analysis for the characterization of the immunological status in different types of tumors and its application for the discrimination of different immunological scenarios

Presentation

Get to know us better

Research Staff

The people who make it all possible

Eloisa Jantus Lewintre

Carlos Camps Herrero

Silvia Calabuig Fariñas

Macarena Ferrero Gimeno

Jose Vicente Bagan Sebastian

Ricardo Guijarro Jorge

Miguel Martorell 

Ana Blasco Cordellat

Alfonso Berrocal Jaime

Vega Iranzo González-cruz

Eva Escorihuela Alares

Andrea Moreno Manuel

Susana Torres Martinez

Publications

Our scientific contributions

dPCR application in liquid biopsies: divide and conquer
A. MORENO-MANUEL, S. CALABUIG-FARINAS, A. OBRADOR-HEVIA, A. BLASCO, A. FERNANDEZ-DIAZ, R. SIRERA, C. CAMPS and E. JANTUS-LEWINTRE
EXPERT REVIEW OF MOLECULAR DIAGNOSTICS, 2021 ,  Vol. 21,  pag. 3-15

CD5 and CD6 as immunoregulatory biomarkers in non-small cell lung cancer
A. MORENO-MANUEL, E. JANTUS-LEWINTRE, I. SIMOES, F. ARANDA, S. CALABUIG-FARINAS, E. CARRERAS, S. ZUNIGA, Y. SAENGER, R. ROSELL, C. CAMPS, F. LOZANO and R. SIRERA
Translational Lung Cancer Research, 2020 ,  Vol. 9,  pag. 1074

Development of a Multicriteria Decision Analysis Framework for Evaluating and Positioning Oncologic Treatments in Clinical Practice.
Camps C, Badia X, García-Campelo R, García-Foncillas J, López R, Massuti B, Provencio M, Salazar R, Virizuela J and Guillem V
Jco Oncology Practice, 2020 ,  Vol. 16,  pag. e298-e305

Osimertinib and dihydroartemisinin: a novel drug combination targeting head and neck squamous cell carcinoma.
Chaib I, Cai X, Llige D, Santarpia M, Jantus-Lewintre E, Filipska M, Pedraz C, Cui J, Yang J, Miao J, Sun R, Bracht JWP, Ito M, Codony-Servat J, Karachaliou N, Aguilar A, Rosell R and Cao P
Annals of Translational Medicine, 2019 ,  Vol. 7,  pag. 651-651

Lung tumorspheres reveal cancer stem cell-like properties and a score with prognostic impact in resected non-small-cell lung cancer
Herreros-Pomares A, de-Maya-Girones JD, Calabuig-Fariñas S, Lucas R, Martínez A, Pardo-Sánchez JM, Alonso S, Blasco A, Guijarro R, Martorell M, Escorihuela E, Chiara MD, Duréndez E, Gandía C, Forteza J, Sirera R, Jantus-Lewintre E, Farràs R and Camps C
Cell Death & Disease, 2019 ,  Vol. 10,  pag. 660-660

FUNDING

Thank you for supporting us